Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

ClinicalTrials.gov ID: NCT07608354

Public ClinicalTrials.gov record NCT07608354. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Study identification

NCT ID
NCT07608354
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
326 participants

Conditions and interventions

Interventions

Drug · Biological · Other

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2026
Primary completion
Feb 5, 2029
Completion
Feb 5, 2029
Last update posted
Jul 13, 2026

2026 – 2029

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
Research Site La Jolla California 92037
Research Site San Francisco California 94115
Research Site Stanford California 94305
Research Site Aurora Colorado 80045
Research Site Washington D.C. District of Columbia 20010
Research Site Jacksonville Florida 32224
Research Site Miami Florida 33176
Research Site Weston Florida 33331
Research Site Chicago Illinois 60637
Research Site Boston Massachusetts 02115
Research Site Kansas City Missouri 64111
Research Site St Louis Missouri 63110
Research Site New York New York 10032
Research Site Chapel Hill North Carolina 27599
Research Site Durham North Carolina 27710
Research Site Cleveland Ohio 44195
Research Site Portland Oregon 97239
Research Site Danville Pennsylvania 17822
Research Site Philadelphia Pennsylvania 19104
Research Site Germantown Tennessee 38138
Research Site Dallas Texas 75390
Research Site Houston Texas 77030
Research Site Salt Lake City Utah 84132
Research Site Falls Church Virginia 22042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07608354, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07608354 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →